Harrow Inc. (HROW)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Harrow Successfully Manufactures Triesence; Management Credibility Soars
Harrow announced the successful production of the notoriously hard to manufacture drug, Triesence. There were many doubters, but management has been proven right in its confidence. This will result in $1.50 of incremental FCF/share in 2025, and then up from there, so that Triesence may by itself be worth more than the current share price. There are huge synergies with Iheezo, as the same buyers can be targeted for both drugs.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
